X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ASTRAZENECA PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ASTRAZENECA PHARMA ORCHID PHARMA LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x -0.1 154.7 - View Chart
P/BV x 0.1 24.0 0.5% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ASTRAZENECA PHARMA
Mar-14
ORCHID PHARMA LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,285 15.1%   
Low Rs35634 5.5%   
Sales per share (Unadj.) Rs276.5189.6 145.8%  
Earnings per share (Unadj.) Rs-79.2-0.2 38,904.4%  
Cash flow per share (Unadj.) Rs-43.53.8 -1,130.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.968.6 78.6%  
Shares outstanding (eoy) m70.4525.00 281.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.45.1 8.2%   
Avg P/E ratio x-1.4-4,712.7 0.0%  
P/CF ratio (eoy) x-2.6249.6 -1.1%  
Price / Book Value ratio x2.114.0 15.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,06723,988 33.6%   
No. of employees `0002.81.6 179.6%   
Total wages/salary Rs m2,5271,605 157.5%   
Avg. sales/employee Rs Th6,956.13,040.2 228.8%   
Avg. wages/employee Rs Th902.51,029.2 87.7%   
Avg. net profit/employee Rs Th-1,993.0-3.3 61,041.9%   
INCOME DATA
Net Sales Rs m19,4774,740 410.9%  
Other income Rs m40792 442.1%   
Total revenues Rs m19,8844,832 411.5%   
Gross profit Rs m1,103-130 -849.5%  
Depreciation Rs m2,519101 2,489.3%   
Interest Rs m5,2270-   
Profit before tax Rs m-6,236-139 4,489.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511139 367.9%   
Tax Rs m-1255 -2,459.7%   
Profit after tax Rs m-5,580-5 109,632.6%  
Gross profit margin %5.7-2.7 -206.7%  
Effective tax rate %2.0-3.7 -54.8%   
Net profit margin %-28.7-0.1 26,679.0%  
BALANCE SHEET DATA
Current assets Rs m11,0142,726 404.0%   
Current liabilities Rs m32,0602,435 1,316.6%   
Net working cap to sales %-108.16.1 -1,757.6%  
Current ratio x0.31.1 30.7%  
Inventory Days Days9574 128.6%  
Debtors Days Days3441 82.3%  
Net fixed assets Rs m29,4401,035 2,843.6%   
Share capital Rs m70550 1,409.0%   
"Free" reserves Rs m2,043942 216.7%   
Net worth Rs m3,8001,716 221.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,5104,156 1,119.1%  
Interest coverage x-0.2NM-  
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.1 36.7%   
Return on assets %-0.8-0.1 620.6%  
Return on equity %-146.9-0.3 49,509.1%  
Return on capital %-3.70-  
Exports to sales %37.95.7 664.4%   
Imports to sales %22.66.5 350.1%   
Exports (fob) Rs m7,378270 2,730.4%   
Imports (cif) Rs m4,406306 1,438.5%   
Fx inflow Rs m7,513375 2,005.7%   
Fx outflow Rs m5,649470 1,201.5%   
Net fx Rs m1,865-96 -1,951.3%   
CASH FLOW
From Operations Rs m1,682-8 -20,761.7%  
From Investments Rs m-9,860-146 6,767.6%  
From Financial Activity Rs m6,644862 770.6%  
Net Cashflow Rs m-1,535709 -216.7%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 0.3 1,533.3%  
FIIs % 3.3 15.7 21.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 9.1 607.7%  
Shareholders   84,811 12,856 659.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   VENUS REMEDIES  MERCK LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Nov 20, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - DR. REDDYS LAB COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS